Company overview
Aqdot develops and licenses AqFresh™ supramolecular chemistry technology using cucurbiturils for odour and VOC elimination, with applications in pharmaceutical encapsulation and controlled release. The platform supports targeted molecule capture and triggerable release, suitable for pharmaceutical industries alongside household, personal care, and agrichemicals. It offers drop-in solutions validated in industrial trials across over 10 industries, registered without hazard labelling in the EU.
Aqdot is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include aqdot, aqfresh, supramolecular chemistry, odour elimination, pharma encapsulation.
Structured facts
- Website
- https://aqdot.com/
- Markets served
- United States & Americas
- Keywords
- aqdot, aqfresh, supramolecular chemistry, odour elimination, pharma encapsulation
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What capabilities does Aqdot offer for pharmaceutical applications?
- Aqdot's AqFresh™ technology enables controlled encapsulation and triggered release of molecules using cucurbiturils, applicable to pharmaceuticals for advanced delivery systems.
- What regulatory approvals does Aqdot's core technology have?
- Aqdot's core technology, AqTMBit, is registered in the EU without hazard or classification labelling for health and environment. It holds four patents protecting the platform.
- In which geographies does Aqdot operate and license its technology?
- Headquartered in Cambridge, England, Aqdot licenses its technology globally, with EU regulatory registration and launches in over 10 industries worldwide.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
